Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
13 Juin 2024 - 2:28PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-163
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of June 2024
Alterity
Therapeutics Limited
(Name
of Registrant)
Level 14, 350 Collins Street,
Melbourne, Victoria 3000 Australia
(Address
of Principal Executive Office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
This
Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980
and 333-228671) and our
Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417
and 333-250076)
ALTERITY
THERAPEUTICS LIMITED
(a
development stage enterprise)
The
following exhibits are submitted:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Alterity Therapeutics Limited |
|
|
|
By: |
/s/ Geoffrey P. Kempler |
|
|
Geoffrey P. Kempler |
|
|
Chairman |
Date:
June 13, 2024
2
Exhibit 99.1
Alterity Therapeutics to Present
at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
MELBOURNE, AUSTRALIA AND SAN
FRANCISCO, USA – 13 June 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),
a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David
Stamler, M.D., Chief Executive Officer will present a company overview at the MST Access ‘Hidden Gems in Life Sciences’ webinar
on Thursday, 13 June 2024 in Australia / Wednesday, 12 June 2024 in the United States.
Details are listed below and registration
is required.
Webcast details
AUSTRALIA PARTICIPANTS:
|
Date: |
Thursday, 13 June 2024 |
|
Time: |
1:30 p.m. AEST (Sydney/Melbourne) |
UNITED STATES PARTICIPANTS:
|
Date: |
Wednesday, 12 June 2024 |
|
Time: |
8:30 p.m. Pacific
Time |
|
|
11:30 p.m. Eastern Time |
To join the presentation, please click the webinar link
here.
Investors will have the opportunity to ask questions during
the call, at the conclusion of the presentation.
A recording of the webinar will be made available on the Alterity
Therapeutics website after the event, which you can access here: www.alteritytherapeutics.com.
About Alterity Therapeutics Limited
Alterity Therapeutics
is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative
diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being
evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating
patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne,
Australia, and San Francisco, California, USA. For further information please visit the Company’s website at
www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity
Therapeutics Limited.
Investor and Media Contacts:
Australia
Hannah Howlett
we-aualteritytherapeutics@we-worldwide.com
+61 450 648 064
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
Alterity Therapeutics (NASDAQ:ATHE)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Alterity Therapeutics (NASDAQ:ATHE)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024